News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Another Novartis AG (NVS) Manufacturing Facility Gets an FDA Lashing



6/5/2013 7:34:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Novartis employees may take ceo Joe Jimenez seriously when he insists that quality matters (remember this?), but the FDA is not taking him at his word. Once again, the agency has issued the drugmaker a warning letter and, this time, the subject is the Ebewe Pharma generic injectables business in Austria, which last year experienced production problems that led to shortages and at least one product ban. The warning letter is only the latest sent by the FDA to Novartis concerning manufacturing issues at different facilities. Over the past two years, the agency has found infractions at a Sandoz plant in Canada and two others in Colorado and North Carolina in the US (see here and here), and the drugmaker also failed repeated inspections at a Nebraska plant that has since scaled back production to a select number of products.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES